Researchers found that use of immunosuppressive medication was a strong protective factor, associated with a 60% reduction in ...

United Health Foundation, the charitable branch of UnitedHealth Group, awarded more than $7 million in grants to ...

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

An expert discusses the existing gaps in atopic dermatitis (AD) management, promising areas of research to address unmet needs, and key takeaways from the discussion for the managed care audience ...

An expert discusses key considerations dermatologists should keep in mind when integrating newer therapies into their clinical practice, including implementing protocols for patient monitoring and ...

The Xpert MTB/Ultra molecular diagnostic test may become a viable option for detecting tuberculosis (TB) in the stool of ...

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...